Pharmaceutical Moderna wants full approval of its corona vaccine for use in the United States. The company has started a process for this.
The drug is still allowed as part of an emergency decision.
The application comes a few weeks after Pfizer and its German partner BioNTech also requested full approval for their drug in the US.
Getting full approval for the vaccines, which play an essential role in countries’ vaccination strategies worldwide, could be an important step in dispelling vaccine doubts. This is a growing concern in the US and other affluent countries, according to experts.
Moderna will submit more data to the Food and Drug Administration in the coming weeks, requesting a review. Once the ongoing filing is complete, the FDA will notify the company when it is formally accepted for review.
In a so-called “rolling submission”, a drug developer can submit completed parts of the application for review by the FDA. In a normal application, the pharmacist would have to wait for each part of the application to be completed before reviewing the entire application.